• Explore /
  • Poster
  • / Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.

Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.

Abstract Poster

Authors

null

Jian Guan

Houston Methodist Cancer Center, Houston, TX

Jian Guan , Shubham Adroja , Zainub Ajmal , Yuan Gao , Nicholas Spetsieris , Siqi Hu , Raj Satkunasivam , Michael A Brooks , Andrew M. Farach , E. Brian Butler , Brian Miles , Eleni Efstathiou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 85)

DOI

10.1200/JCO.2024.42.4_suppl.85

Abstract #

85

Poster Bd #

C20

Abstract Disclosures

Similar Posters

First Author: Alicia K. Morgans

Poster

2022 ASCO Genitourinary Cancers Symposium

Real-world experience with relugolix.

Real-world experience with relugolix.

First Author: Saro Kasparian

First Author: Fernando C. Maluf

First Author: Bertrand F. Tombal